Oral Decongestant for Acute Bacterial Sinusitis
Pseudoephedrine is the appropriate oral decongestant for symptomatic relief in adults with acute bacterial sinusitis, though recent evidence supporting its efficacy is limited.
Primary Recommendation
The 2025 American Academy of Otolaryngology guideline explicitly discourages oral phenylephrine based on FDA advisory committee findings and multiple RCTs showing lack of efficacy 1. For oral decongestant therapy beyond 3-5 days of topical use, pseudoephedrine is the recommended option, though clinicians should note that recent high-quality evidence for its effectiveness is lacking 1.
Algorithmic Approach to Decongestant Selection
First-Line: Topical Therapy (Days 1-3)
- Oxymetazoline (topical) for 3-5 days maximum
- Meta-analysis supports benefit 1
- Critical caveat: Warn patients about rhinitis medicamentosa (rebound congestion) with use beyond 3 days
Second-Line: Oral Therapy (If needed beyond Day 3-5)
- Pseudoephedrine is the only viable oral option 1, 2
- Counsel patients on:
- Contraindications: elevated blood pressure and heart rate
- "Behind the counter" access requirements
- Limited recent evidence base
What NOT to Use
- Oral phenylephrine: FDA-backed RCTs show inefficacy 1
- First-generation antihistamines: No effect on nasal obstruction, rhinorrhea, or sneezing; avoid in older adults 1
Important Clinical Context
The penicillin allergy status mentioned in your question is relevant for antibiotic selection (amoxicillin ± clavulanate as first-line), but does not affect decongestant choice 3, 4. Decongestants are adjunctive symptomatic therapy and have no drug interactions with penicillin-class antibiotics.
Older literature from 1981 suggests phenylephrine as an oral option 2, but this has been definitively superseded by 2023 FDA findings incorporated into the 2025 guideline 1.
Additional Symptomatic Measures
While not oral decongestants, consider these evidence-based adjuncts: